Galenica - Media releaseshttp://www.galenica.comIn our media releases, you will find all news around the Galenica Group and its companies at a glance. For further inquiries, our extensive archive is at your disposal.enMon, 23 Jan 2017 01:30:42 +0100info@galenica.com (Galenica)webmaster@galexis.com (Webmaster Galenica)http://www.galenica.com/wAssetsGroup/img/logos/galenica.gifGalenica - Media releaseshttp://www.galenica.comWeblicationGRID60Planned division of the Galenica GroupThe preparations for the division of the Galenica Group planned for 2017 are on track. The per-formances in recent months and the agreements concluded in 2016 have further strengthened Vifor Pharma and Galenica Santé. Both Business units are therefore prepared to successfully grow further in the future as independent companies. http://www.galenica.com/en/medien/medienmitteilungen/2017/20170118_7744795952_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2017/20170118_7744795952_meldung.phpThu, 19 Jan 2017 00:00:00 +0100Galenica Ltd.Vifor Pharma Ltd.2016 sales of the Galenica GroupThe Galenica Group continued its dynamic growth in 2016, increasing consolidated net sales by 8.6% to CHF 4,118.4 million. Both Business units, Vifor Pharma and Galenica Santé, contributed to this growth. Management confirms the profit and EBIT forecasts for financial year 2016 communicated in October 2016. The Galenica Group confirms its intention to develop Vifor Pharma and Galenica Santé into two independent listed companies in 2017. A separate press release has been issued today on the status of the current preparatory work.http://www.galenica.com/en/medien/medienmitteilungen/2017/20170118_2697935633_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2017/20170118_2697935633_meldung.phpThu, 19 Jan 2017 00:00:00 +0100Galenica Ltd.Vifor Pharma Ltd.The Galenica Group is taking over SD wholesaler PharmapoolThe Galenica Group is taking over the physicians wholesaler Pharmapool Ltd. through its own pharmaceutical wholesale company Galexis Ltd. The company will continue to offer its services on the market under its current name and for management purposes will be integrated into Galenica Santé as part of the Services Business sector, which will be able to exploit attractive potential synergies in the future.http://www.galenica.com/en/medien/medienmitteilungen/2017/20170111_5562317230_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2017/20170111_5562317230_meldung.phpWed, 11 Jan 2017 00:00:00 +0100Galenica Ltd.Change to the shareholder structure of the Galenica GroupSprint Investments 2 no longer holds stake in Galenica Group Broad placement of shares among various investors with long-term investment focus http://www.galenica.com/en/medien/medienmitteilungen/2017/20170109_7172263064_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2017/20170109_7172263064_meldung.phpMon, 09 Jan 2017 00:00:00 +0100Galenica Ltd.Vifor Pharma and ChemoCentryx announce expansion of Kidney Health Alliance to include CCX140 to treat renal diseasesVifor Pharma and ChemoCentryx announce expansion of Kidney Health Alliancehttp://www.galenica.com/en/medien/medienmitteilungen/2016/20161223_2043195966_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2016/20161223_2043195966_meldung.phpFri, 23 Dec 2016 00:00:00 +0100Galenica Ltd.Swisscom Health to take over Galenica practice information systemApprox. 2,000 doctors currently use Swisscom Health’s curaPrax. The Swisscom subsidiary is now to double its regular customers with the takeover of Galenica's TriaMed® practice software and extends its knowledge of large practices and chains. Galenica and Swisscom intend to intensify their cooperation on networking within Swiss healthcare system.http://www.galenica.com/en/medien/medienmitteilungen/2016/20161209_5126241803_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2016/20161209_5126241803_meldung.phpFri, 09 Dec 2016 00:00:00 +0100Galenica Ltd.FDA Approves Supplemental New Drug Application for Veltassa® Removing Boxed Warning Regarding Drug-Drug InteractionsFDA Approves Supplemental New Drug Application for Veltassa® Removing Boxed Warning Regarding Drug-Drug Interactionshttp://www.galenica.com/en/medien/medienmitteilungen/2016/20161128_7839495797_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2016/20161128_7839495797_meldung.phpMon, 28 Nov 2016 00:00:00 +0100Galenica Ltd.Vifor Pharma Ltd.New management at Vifor Pharma and new Galenica Group CFO designatedThe Board of Directors of the Galenica Group has designated Stefan Schulze, currently CEO of Vifor Fresenius Medical Care Renal Pharma (VFMCRP), as Chief Operating Officer (COO) and President of the Executive Committee of Vifor Pharma. Under the proven leadership of the Executive Chairman of the Board of Directors, Etienne Jornod, Stefan Schulze will take over this position from the Annual General Meeting of Galenica Ltd. in May 2017.http://www.galenica.com/en/medien/medienmitteilungen/2016/20161006_6705677878_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2016/20161006_6705677878_meldung.phpThu, 06 Oct 2016 00:00:00 +0200Galenica Ltd.Vifor Pharma Ltd.Galenica completes acquisition of RelypsaGalenica completes acquisition of Relypsa, strengthening Vifor Pharma’s position in cardio-renal therapieshttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160902_3046390678_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160902_3046390678_meldung.phpFri, 02 Sep 2016 00:00:00 +0200Galenica Ltd.Vifor Pharma Ltd.Galenica announces Expiration of Cash Tender Offer for RelypsaGalenica Group today announced that its tender offer to purchase the outstanding shares of common stock of Relypsa, Inc., (NASDAQ: RLYP) at USD 32.00 per share, net to the seller in cash, without interest and less any applicable withholding taxes, expired at 12:00 midnight New York time, at the end of the day on Wednesday, August 31, 2016. The tender offer was effected by the indirect wholly owned subsidiary of Galenica, Vifor Pharma USA Inc.http://www.galenica.com/en/medien/medienmitteilungen/2016/20160901_6658998799_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160901_6658998799_meldung.phpThu, 01 Sep 2016 00:00:00 +0200Galenica Ltd.Vifor Pharma Ltd.Galenica Group half year results 2016In the first half of 2016, the Galenica Group increased consolidated net sales by 12.1% to CHF 2,009.3 million. Net profit before deduction of minority interests rose by 23.3% to CHF 194.6 million and net profit after deduction of minority interests rose by 21.5% to CHF 158.9 million. On a comparable basis – without accounting components of IAS 19 – net profit before deduction of minority interests rose by 23.5% to CHF 201.7 million and net profit after deduction of minority interests increased by 21.8% to CHF 166.0 million.http://www.galenica.com/en/medien/medienmitteilungen/2016/20160809_7518492669_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160809_7518492669_meldung.phpTue, 09 Aug 2016 00:00:00 +0200Galenica Ltd.Vifor Pharma Ltd.Galenica commences Tender Offer for RelypsaGalenica Group today announced that its indirect wholly owned subsidiary, Vifor Pharma USA Inc., is commencing today its previously announced tender offer for any and all outstanding shares of common stock of Relypsa, Inc. (NASDAQ: RLYP) at a price of USD 32.00 per share in cash, without interest and less applicable withholding taxes. The tender offer is being made in connection with the Agreement and Plan of Merger, dated July 20, 2016, among Galenica Ltd., Vifor Pharma USA Inc. and Relypsa, Inc.http://www.galenica.com/en/medien/medienmitteilungen/2016/20160804_8321945884_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160804_8321945884_meldung.phpThu, 04 Aug 2016 00:00:00 +0200Galenica Ltd.Vifor Pharma Ltd.Galenica to acquire Relypsa to strengthen its Business unit Vifor PharmaGalenica to acquire Relypsa to strengthen its Business unit Vifor Pharmahttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160721_2035311829_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160721_2035311829_meldung.phpThu, 21 Jul 2016 00:00:00 +0200Galenica Ltd.Vifor Pharma Ltd.Vifor Pharma strengthens company management – division of Galenica to take place once the new management is in placeVifor Pharma to further strengthen company management to ensure continued strong growth. The Galenica Group will be divided once the new CEO of Vifor Pharma has been appointed and settled into their role.http://www.galenica.com/en/medien/medienmitteilungen/2016/20160524_6365575317_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160524_6365575317_meldung.phpTue, 24 May 2016 00:00:00 +0200Vifor Pharma to license commercialisation rights to Pfizer’s proposed biosimilar, Retacrit™, in the field of nephrology in the USVifor Pharma expands ESA product portfolio with rights to commercialise Pfizer’s proposed epoetin alfa biosimilar, Retacrit™, in the US dialysis markethttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160524_1088187068_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160524_1088187068_meldung.phpTue, 24 May 2016 00:00:00 +0200Galenica Ltd.The Galenica Group plans to take over SD wholesaler PharmapoolGalenica plans to acquire physicians wholesaler Pharmapool through its own wholesale com-pany Galexis. As a result of the integration, both firms stand to benefit from interesting synergies arising from joint activities with self-dispending physicians and a strengthened base for consolidating and further expanding the business. Pharmapool Ltd. will continue to offer its services on the market under its current name, while it will be integrated into the Galenica Group as part of the Services Business sector.http://www.galenica.com/en/medien/medienmitteilungen/2016/20160518_2275135927_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160518_2275135927_meldung.phpFri, 20 May 2016 00:00:00 +0200Galenica Ltd.Change to the shareholder structure of the Galenica GroupKKR and Stefano Pessina reduce the stake held through Sprint Investments 2 GmbH from 25% to slightly above 20%, thereby significantly increasing the free float of the Galenica share (shares in circulation). http://www.galenica.com/en/medien/medienmitteilungen/2016/20160511_3114476014_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160511_3114476014_meldung.phpWed, 11 May 2016 09:59:08 +0200Galenica Ltd.Vifor Pharma licenses marketing rights to CCX168 in certain territoriesVifor Pharma Licenses Rights to Commercialise ChemoCentryx’s Orally-Administered Complement 5aR Inhibitor CCX168 for Orphan and Rare Renal Diseases in Europe and Certain Other Major Marketshttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160510_5060272735_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160510_5060272735_meldung.phpTue, 10 May 2016 00:00:00 +0200Galenica Ltd.Vifor Fresenius Medical Care Renal Pharma acquires marketing rights to RAYALDEE®Vifor Fresenius Medical Care Renal Pharma (VFMCRP), a common company of Galenica and Fresenius Medical Care, and OPKO Health (NYSE: OPK), have entered into a collaboration and license agreement for the development and commercialisation of RAYALDEE® in Europe, Canada, Mexico, Australia, South Korea and certain other international markets for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) and vitamin D insufficiency. Under the terms of the agreement, the parties will also collaborate to develop and commercialise RAYALDEE® for the treatment of SHPT in dialysis patients, and OPKO has granted VFMCRP an option to acquire rights to the US market for treatment of dialysis patients.http://www.galenica.com/en/medien/medienmitteilungen/2016/20160509_7812127617_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160509_7812127617_meldung.phpMon, 09 May 2016 00:00:00 +0200Galenica Ltd.2016 Annual General Meeting of Galenica Ltd.88th Annual General Meeting of Galenica Ltd.: Shareholders approve all proposals submitted by the Board of Directors http://www.galenica.com/en/medien/medienmitteilungen/2016/20160426_1813841652_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160426_1813841652_meldung.phpThu, 28 Apr 2016 00:00:00 +0200Galenica Ltd.Patiromer submitted to EMA to seek approval in the EUVifor Fresenius Medical Care Renal Pharma submits marketing authorisation application requesting European approval of Patiromer for treatment of hyperkalemiahttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160425_1448060631_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160425_1448060631_meldung.phpMon, 25 Apr 2016 00:00:00 +0200Galenica Ltd.Galenica 2015: profit increased for the 20th consecutive yearThe Galenica Group recorded profit growth for the 20th consecutive year in 2015. Allowing for negative effects due to IAS 19, net profit before deduction of minority interests rose by 18.6% to CHF 370.0 million and by 5.8% to CHF 301.1 million after deduction of minority interests. On a comparable basis – without negative effects due to IAS 19 – net profit before deduction of minority interests rose by 21.1% and net profit after deduction of minority interests by 8.6%.http://www.galenica.com/en/medien/medienmitteilungen/2016/20160315_5463965006_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160315_5463965006_meldung.phpTue, 15 Mar 2016 00:00:00 +0100Galenica Ltd.Galenica in 2015: strong sales growth and confirmation of the 20th consecutive increase in profitThe Galenica Group grew strongly in 2015, increasing consolidated net sales by 11.0% to CHF 3,791.6 million. This growth is broadly based, with contributions from all areas. Group management has confirmed the forecast communicated in the half-year report 2015 that it will increase profit, both before and after deduction of minority interests, for the 20th consecutive year. Preparatory work for the transformation of Vifor Pharma and Galenica Santé into two inde-pendent companies is proceeding as planned, with the goal of dividing the Galenica Group in the fourth quarter of 2016. Das Management bestätigt die zum Halbjahresabschluss 2015 kommunizierte Prognose, für das Geschäftsjahr zum 20. Mal in Folge den Gewinn sowohl vor als auch nach Abzug von Minderheiten zu erhöhen. Die Vorbereitungsarbeiten Vifor Pharma und Galenica Santé zu eigenständigen Unternehmen zu entwickeln, verlaufen planmässig mit dem Ziel, die Galenica Gruppe im 4. Quartal 2016 aufzuteilen.http://www.galenica.com/en/medien/medienmitteilungen/2016/20160119_2305097974_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2016/20160119_2305097974_meldung.phpThu, 21 Jan 2016 00:00:00 +0100Galenica Ltd.Galenica plans to divide the Group in the 4th quarter of 2016 Galenica plans to divide the Group in the 4th quarter of 2016 http://www.galenica.com/en/medien/medienmitteilungen/2015/20151201_2818825591_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2015/20151201_2818825591_meldung.phpTue, 01 Dec 2015 06:01:35 +0100Galenica Ltd.Kissei receives Japanese approval for P-TOL® (in the USA and Europe commercialized as Velphoro®) Sucroferric oxyhydroxide® receives approval by the Ministry of Health, Labour and Welfare in Japan for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis under the name “P-TOL®” (in the USA and Europe commercialized as Velphoro®)http://www.galenica.com/en/medien/medienmitteilungen/2015/20150930_1901056353_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2015/20150930_1901056353_meldung.phpWed, 30 Sep 2015 05:56:41 +0200Galenica Ltd.Vifor Pharma Ltd.Vifor Fresenius Medical Care Renal Pharma enters into partnership with Relypsa to commercialise Patiromer FOSVifor Fresenius Medical Care Renal Pharma (VFMCRP), a common company of Galenica and Fresenius Medical Care, and Relypsa, Inc. have entered into an exclusive partnership to commercialise the potassium binder Patiromer for Oral Suspension (Patiromer FOS) in Europe and additional territories. Patiromer FOS is an investigational drug of Relypsa for the treatment of hyperkalaemia that occurs most frequently in chronic kidney disease and heart failure patients. It represents an ideal complement to the existing product portfolio of VFMCRP for patients with chronic kidney disease and iron deficiency.http://www.galenica.com/en/medien/medienmitteilungen/2015/20150810_4252598166_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2015/20150810_4252598166_meldung.phpTue, 11 Aug 2015 00:01:00 +0200Galenica Ltd.Galenica Group half-year results 2015 Galenica Group half-year results 2015 http://www.galenica.com/en/medien/medienmitteilungen/2015/20150811_2080790829_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2015/20150811_2080790829_meldung.phpTue, 11 Aug 2015 00:00:00 +0200Galenica Ltd.Galenica Santé: new strategic priorities and changes to the organisational structureBased on the vision of the Galenica Group of developing the Vifor Pharma and Galenica Santé Business units into two independent listed companies, Galenica Santé has defined new strategic priorities: in future, Galenica Santé will play an even more active and dynamic role in the market. To ensure implementation of the strategy at operational level, the organisational structure is being changed: Galenica Santé will be organised into the three Business sectors Products & Brands, Retail and Services. Alongside the introduction of the new organisational structure, the management positions for each of the Business sectors are also being newly filled. To support preparations for a possible division of the Group and future strategic projects, the new “Strategic Projects” function will also be created at Group level. All changes will come into effect on 1 September 2015.http://www.galenica.com/en/medien/medienmitteilungen/2015/20150703_5205694769_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2015/20150703_5205694769_meldung.phpFri, 03 Jul 2015 00:00:00 +0200Galenica Ltd.Galenica and Roche enter into exclusive license agreement for the commercialisation of Mircera® in the USGalenica and Roche have entered into an exclusive license agreement for the commercialisation of Roche’s drug Mircera® in the US and Puerto Rico. Mircera® is a prescription medicine used to treat symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients and represents an ideal complement to the existing product portfolio of Galenica for patients with CKD and iron deficiency.http://www.galenica.com/en/medien/medienmitteilungen/2015/20150528_4356928162_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2015/20150528_4356928162_meldung.phpThu, 28 May 2015 00:00:01 +0200Galenica Ltd.Vifor Pharma Ltd.Vifor Fresenius Medical Care Renal Pharma to expand its business activitiesVifor, Fresenius, Medical, Care, Renal, Pharmahttp://www.galenica.com/en/medien/medienmitteilungen/2015/20150528_5729813457_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2015/20150528_5729813457_meldung.phpThu, 28 May 2015 00:00:00 +0200Galenica Ltd.2015 Annual General Meeting of Galenica Ltd.2015 Annual General Meeting of Galenica Ltd.http://www.galenica.com/en/medien/medienmitteilungen/2015/20150505_6155935299_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2015/20150505_6155935299_meldung.phpThu, 07 May 2015 00:00:00 +0200Galenica Ltd.Measures to ensure strategy implementationMeasures to ensure strategy implementationhttp://www.galenica.com/en/medien/medienmitteilungen/2015/20150413_8809358676_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2015/20150413_8809358676_meldung.phpMon, 13 Apr 2015 00:00:00 +0200Galenica Ltd.Results of the Galenica Group for 2014Results of the Galenica Group for 2014http://www.galenica.com/en/medien/medienmitteilungen/2015/20150310_7876067106_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2015/20150310_7876067106_meldung.phpTue, 10 Mar 2015 00:00:00 +0100Galenica Ltd.Galenica Group sales 2014Galenica Group sales 2014http://www.galenica.com/en/medien/medienmitteilungen/2015/20150121_6001794815_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2015/20150121_6001794815_meldung.phpWed, 21 Jan 2015 00:00:00 +0100Galenica Ltd.Velphoro® receives EU Marketing AuthorisationVelphoro® receives EU Marketing Authorisationhttp://www.galenica.com/en/medien/medienmitteilungen/2014/20140827_7793895588_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2014/20140827_7793895588_meldung.phpWed, 27 Aug 2014 00:00:00 +0200Galenica Ltd.Galenica lays foundation for two listed, independent companiesGalenica lays foundation for two listed, independent companieshttp://www.galenica.com/en/medien/medienmitteilungen/2014/20140812_3085714023_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2014/20140812_3085714023_meldung.phpTue, 12 Aug 2014 03:00:00 +0200Galenica Ltd.Vifor Pharma Ltd.Results of the Galenica Group for the first half of 2014Results of the Galenica Group for the first half of 2014http://www.galenica.com/en/medien/medienmitteilungen/2014/20140812_5184803583_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2014/20140812_5184803583_meldung.phpTue, 12 Aug 2014 00:00:00 +0200Galenica Ltd.Velphoro® (PA21) receives Positive CHMP Opinion Velphoro® (PA21) recommended for approval in the European Union for the treatment of hyperphosphatemia in adult Chronic Kidney Disease patients on dialysishttp://www.galenica.com/en/medien/medienmitteilungen/2014/20140627_2471302282_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2014/20140627_2471302282_meldung.phpFri, 27 Jun 2014 00:00:00 +0200Galenica Ltd.86th Annual General Meeting of Galenica Ltd.: Shareholders approve all proposals submitted by the Board of Directors2014 Annual General Meeting of Galenica Ltd.http://www.galenica.com/en/medien/medienmitteilungen/2014/20140508_6426597618_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2014/20140508_6426597618_meldung.phpThu, 08 May 2014 08:41:24 +0200Galenica Ltd.Double-digit growth in profits for the 18th consecutive year – dividend increase to CHF 14 per registered share proposedResults of the Galenica Group for 2013http://www.galenica.com/en/medien/medienmitteilungen/2014/20140305_1751642108_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2014/20140305_1751642108_meldung.phpTue, 11 Mar 2014 00:00:00 +0100Galenica Ltd.Galenica posts solid sales growth for 2013 and confirms double-digit growth in profitGalenica posts solid sales growth for 2013 and confirms double-digit growth in profithttp://www.galenica.com/en/medien/medienmitteilungen/2014/20140121_1132498659_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2014/20140121_1132498659_meldung.phpTue, 21 Jan 2014 00:00:00 +0100Galenica Ltd.Velphoro® (PA21) receives US FDA approval for the treatment ofhyperphosphatemia in Chronic Kidney Disease Patients on dialysisVelphoro® (PA21) receives US FDA approval for the treatment of hyperphosphatemia in Chronic Kidney Diseasehttp://www.galenica.com/en/medien/medienmitteilungen/2013/20131122_6119169377_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2013/20131122_6119169377_meldung.phpThu, 28 Nov 2013 00:00:00 +0100Galenica Ltd.Galenica achieves significant milestones in the first half of 2013 and announces for 2013 profit growth for the 18th consecutive yearThe Galenica Group performed well in a complex market environment during the first six months of 2013. Net sales increased by 2.0% to CHF 1,648.6 million year-on-year. Profit before and after minority interests increased by around 7% on a comparable basis. Taking into account the one-time effects of IAS 19, profit increased even more significantly by 20.3% before minority interests and by 21.8% after minority interests. Galenica therefore anticipates that the Group will record double-digit profit growth for the 18th consecutive year in 2013, this time both before and after minority interests.http://www.galenica.com/en/medien/medienmitteilungen/2013/20130813_5778787699_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2013/20130813_5778787699_meldung.phpTue, 13 Aug 2013 00:00:00 +0200Galenica Ltd.Injectafer® receives US FDA approval for the treatment of Iron Deficiency AnaemiaInjectafer® receives US FDA approval for the treatment of Iron Deficiency Anaemiahttp://www.galenica.com/en/medien/medienmitteilungen/2013/20130726_3799040321_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2013/20130726_3799040321_meldung.phpFri, 26 Jul 2013 05:29:27 +0200Galenica Ltd.The Galenica Group acquires 49% stake in pharmacy Bahnhof Apotheke ZurichThe Galenica Group has acquired a 49% stake in the Bahnhof Apotheke Zurich, thereby expanding its network with a highly successful and strategically well-positioned pharmacy. With over 350,000 commuters and travellers passing through every day, Zurich’s main station is the most frequented place in Switzerland. In concluding this strategic partnership, the sole proprietor joins the leading player in the Swiss pharmacy market, taking a first step in future succession planning. As the majority shareholder, the current owner retains sole responsibility for managing the pharmacy.http://www.galenica.com/en/medien/medienmitteilungen/2013/20130723_5604295749_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2013/20130723_5604295749_meldung.phpTue, 23 Jul 2013 00:00:00 +0200Galenica Ltd.Galenica acquires Medifilm Ltd., expanding its logistic offering with individualised supply of medication to patients in care homesThrough its pharmaceutical wholesaler Galexis, Galenica is acquiring Medifilm Ltd., a leading company in the field of blister packaging for medicines. With the specific services provided by Medifilm Ltd., Galexis will expand its offering to all pharmacies who prepare medicines for pa-tients on an individual basis on behalf of care homes. http://www.galenica.com/en/medien/medienmitteilungen/2013/20130711_6955560480_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2013/20130711_6955560480_meldung.phpThu, 11 Jul 2013 00:00:00 +0200Galenica Ltd.FIND-CKD study demonstrates that Ferinject® reduces need for alternative anaemia treatmentZiel der FIND-CKD-Studie war, die optimale Verabreichungsart und Dosierungsstrategie für Eisentherapie bei Patienten mit chronischer Nierenerkrankung (ND-CKD) und Eisenmangelanämie zu ermitteln. http://www.galenica.com/en/medien/medienmitteilungen/2013/20130710_4301510535_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2013/20130710_4301510535_meldung.phpWed, 10 Jul 2013 00:00:00 +0200Galenica Ltd.85th Annual General Meeting of Galenica Ltd.: Shareholders approve all proposals submitted by the Board of Directors85th Annual General Meeting of Galenica Ltd.http://www.galenica.com/en/medien/medienmitteilungen/2013/20130502_3764580086_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2013/20130502_3764580086_meldung.phpThu, 02 May 2013 00:00:00 +0200Galenica Ltd.PDUFA action date for PA21 New Drug Application set by US FDAFollowing the submission of the New Drug Application (NDA) for PA21, the US Food and Drug Administration (FDA) has announced that it has accepted the filing and assigned a PDUFA (Prescription Drug User Fee Act) target action date of 1 December 2013 to complete its review.http://www.galenica.com/en/medien/medienmitteilungen/2013/20130412_8020710014_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2013/20130412_8020710014_meldung.phpMon, 15 Apr 2013 00:00:00 +0200Galenica Ltd.New PDUFA action date announced by the US FDA for Injectafer® New Drug ApplicationGalenica’s U.S. partner, Luitpold Pharmaceuticals, Inc., has received confirmation from the US Food and Drug Administration (FDA) that the New Drug Application (NDA) for the intravenous iron preparation Injectafer® has been accepted for review with a PDUFA (Prescription Drug User Fee Act) target action date of 30 July, 2013.http://www.galenica.com/en/medien/medienmitteilungen/2013/20130408_4353442069_meldung.phphttp://www.galenica.com/en/medien/medienmitteilungen/2013/20130408_4353442069_meldung.phpMon, 08 Apr 2013 00:00:00 +0200Galenica Ltd.